Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-Asparaginase, IND 100594) or Intravenous Oncaspar in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia.

Trial Profile

A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-Asparaginase, IND 100594) or Intravenous Oncaspar in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Calaspargase pegol (Primary) ; Pegaspargase
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 04 Sep 2018 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 28 Feb 2017 According to a Leadiant Biosciences media release, this trial was originally conducted by Sigma-Tau Pharmaceuticals, Inc. but later on this company's name changed to Leadiant Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top